Stephenson Harwood advises Acacia Pharma on €27 million fundraise
Law firm Stephenson Harwood LLP has advised Acacia Pharma Group plc on its successful €27 million fundraise, through the placing of 10 million new ordinary shares with institutional investors in Europe and the US.
Acacia Pharma is a commercial stage biopharmaceutical company, which is focused on developing and commercialising novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy. The funds provide the group with the financial resources to support the continued launch and commercialisation strategy in the US for its two approved products, BARHEMSYS® and BYFAVO™. The fundraise follows the group's successful €25 million raise in August 2020, on which Stephenson Harwood also advised.
The Stephenson Harwood team was led by corporate partners David Dowding and Anthony Clare, with support from associates Jack Digby and James Gracey. Further assistance was provided by tax partner John Meehan. Stephenson Harwood previously advised Acacia Pharma on its €190 million IPO and listing on Euronext Brussels in 2018.
Bank Degroof Petercam SA/NV acted as sole bookrunner and listing agent in connection with the fundraise.
